Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ONCY files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsOncolytics establishes up to $75M at-the-market equity offering to fund pelareorep trials
Filed April 6, 2026 · Period ending April 6, 2026 · ~1 min read
Key Changes
-
high
Company entered into agreement with Jefferies to sell up to $75M of common stock through at-the-market offerings, with 3% commission on sales. No obligation to sell any shares.
Item 8.01 verify on EDGAR → -
medium
Proceeds will fund clinical development of pelareorep and related R&D expenses, plus operating costs and working capital.
Item 8.01 verify on EDGAR → -
low
Shelf registration statement became effective April 3, 2026, enabling the ATM program.
Item 8.01 verify on EDGAR →
Summary
Oncolytics Biotech established an at-the-market equity offering facility allowing the company to sell up to $75 million of common stock through Jefferies LLC as sales agent. The company has no obligation to sell shares and will pay a 3% commission on any sales.
The ATM structure provides flexible access to capital markets, allowing the company to raise funds opportunistically as needed rather than through a single large offering. Proceeds will fund clinical development of pelareorep, the company's lead drug candidate, along with associated research and development expenses, operating costs, and general corporate purposes.
This is a standard financing mechanism for clinical-stage biotech companies that need ongoing capital to advance drug candidates through trials. The shelf registration enabling this program became effective April 3, 2026. Investors should monitor actual share sales and resulting dilution through future filings.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The Company intends to use any net cash proceeds it receives from the issuance and sale of any Shares in the offering to fund the clinical development of pelareorep and associated research and development expenses, for operating costs and for working capital and general corporate purposes.
Proceeds from any share sales will be used to fund clinical development of pelareorep (the company's lead drug candidate) and related R&D expenses, as well as operating costs and general corporate purposes. This indicates the company is funding ongoing clinical trials and operations through equity financing.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 21, 2026 · How we verify